Key Drivers
- Strong Liquidity
- Deepening Losses
- Weak Cash Flow
AIAI Summary
EVO has shifted from a pipeline-optionality story to a stressed turnaround where real partnered-program progress and grant funding are being overshadowed by worsening losses, negative cash flow, and rising financing/dilution risk, so the stock likely needs clear margin stabilization and self-funding evidence before a re-rate is credible.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Deepening Losses
- •Weak Cash Flow
EVO remains liquid but is becoming riskier, as worsening losses, negative cash flow, and rising leverage outweigh its modest book/sales valuation.
Price Behavior
Key Price Behavior Insights:
- •Failed base
- •Lower lows
- •Near support
EVO has weakened over the last month, with a failed base near $3.00 and lower highs/lows leaving the stock under pressure near key support at $2.70 while resistance remains $3.24-$3.30.
The short-term base near $3.00 broke on
Sentiment & News
Key News Insights:
- •CFO Transition
- •Board Expansion
- •Pipeline Progress
Evotec's latest updates show a smooth CFO handover, governance changes, continued financing via a €116.1 million convertible bond placement, and steady pipeline momentum from grants and partnered R&D.
The news is broadly neutral to mildly positive, as leadership and financing actions support operational flexibility while research updates help sustain investor interest
Similar Companies in Healthcare
Other companies in the same sector with AI ratings